Davita Inc (DVA) Shares Obtained by Axa

Davita Inc (DVA) Shares Obtained by Axa

Axa increased its position in shares of Davita Inc (NYSE:DVA) by 8.4% during the first quarter, Holdings Channel reports. The firm owned 92,532 shares of the company’s stock after buying an additional 7,159 shares during the period. Axa’s holdings in Davita were worth $6,289,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in DVA. SRS Capital Advisors Inc. bought a new stake in Davita during the fourth quarter worth $118,000. Raymond James Trust N.A. bought a new stake in Davita during the first quarter worth $202,000. Advisor Partners LLC bought a new stake in Davita during the first quarter worth $218,000. Wetherby Asset Management Inc. raised its stake in Davita by 3.3% in the first quarter. Wetherby Asset Management Inc. now owns 3,224 shares of the company’s stock worth $219,000 after buying an additional 104 shares during the period. Finally, Pacer Advisors Inc. raised its stake in Davita by 3.0% in the first quarter. Pacer Advisors Inc. now owns 3,422 shares of the company’s stock worth $233,000 after buying an additional 101 shares during the period. 85.31% of the stock is owned by hedge funds and other institutional investors.

Shares of Davita Inc (NYSE DVA) traded down 1.47% during mid-day trading on Friday, reaching $66.43. The company had a trading volume of 1,378,579 shares. Davita Inc has a 1-year low of $54.50 and a 1-year high of $78.77. The firm has a 50-day moving average price of $66.57 and a 200-day moving average price of $65.83. The stock has a market capitalization of $12.93 billion, a price-to-earnings ratio of 10.91 and a beta of 1.02.

Davita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.82 by $0.03. Davita had a net margin of 4.92% and a return on equity of 16.16%. The business had revenue of $3.70 billion for the quarter, compared to analysts’ expectations of $3.69 billion. Equities analysts expect that Davita Inc will post $3.54 earnings per share for the current year.

A number of analysts have recently weighed in on DVA shares. TheStreet raised Davita from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Jefferies Group LLC set a $70.00 price objective on Davita and gave the company a “buy” rating in a research note on Friday, May 26th. Zacks Investment Research raised Davita from a “hold” rating to a “buy” rating and set a $77.00 price objective for the company in a research note on Tuesday, April 18th. Royal Bank of Canada reissued a “hold” rating and set a $62.00 price objective on shares of Davita in a research note on Friday, February 17th. Finally, Goldman Sachs Group Inc reissued a “sell” rating and set a $62.00 price objective on shares of Davita in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $69.50.

In related news, Director Charles Berg sold 8,414 shares of the business’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $65.80, for a total transaction of $553,641.20. Following the completion of the transaction, the director now owns 34,719 shares in the company, valued at approximately $2,284,510.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Javier Rodriguez sold 1,294 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $66.21, for a total value of $85,675.74. Following the completion of the sale, the chief executive officer now owns 99,111 shares of the company’s stock, valued at $6,562,139.31. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,702 shares of company stock valued at $1,495,492. 2.10% of the stock is owned by company insiders.

About Davita

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “DVA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).

Related posts

Leave a Comment